Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | 2026-03-03 05:06:25 | 15.75 | -0.57 | -3.49 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT | 0000873303 | Sarepta Therapeutics, Inc. | US8036071004 | 549300IKDPIED8J8IG21 | 930797222 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 215 FIRST STREET | CAMBRIDGE | MA | 02142 | UNITED STATES | US | 617-274-4000 | 215 FIRST STREET, CAMBRIDGE, MA, 02142 | 215 FIRST STREET, CAMBRIDGE, MA, 02142 | Sarepta Therapeutics, Inc. | — | 1980 | Douglas S. Ingram | 1,314 | http://sarepta.com | 15,054,650,800,000 | 105,418,987 | 104,787,187 | Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. | 2026-02-26 17:26:08 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 15,054,650,800,000 | 4,372,964,885,000 | 40.9389 | 97,032,073 | 3,176,663 | 3.3846 |
| 2023 | 10,681,685,915,000 | 4,120,039,902,000 | 62.7897 | 93,855,410 | 5,873,525 | 6.6758 |
| 2022 | 6,561,646,013,000 | 6,555,439,996,849 | 105,630.405 | 87,981,885 | 832,296 | 0.955 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Louise Rodino-Klapac | Chief Scientific Officer, Executive Vice President | 2024 | 666,706 | — | 772,020 | 436,588 | 16,720 | 2,737,283 |
| Bilal Arif | Executive Vice President | 2024 | 545,200 | — | 772,020 | 358,280 | 18,388 | 2,539,138 |
| Douglas S. Ingram | Chief Executive Officer, President | 2024 | 846,902 | — | 0 | 1,111,148 | 20,036 | 1,978,086 |
| Ian M. Estepan | Chief Financial Officer, Executive Vice President | 2024 | 656,961 | — | 772,020 | 430,206 | 48,085 | 2,752,522 |
| Dallan Murray | Executive Vice President | 2024 | 621,842 | — | 772,020 | 409,435 | 17,776 | 2,666,323 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 835 |
| 2024 | 1,372 |
| 2023 | 1,314 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 2,198,237,000 | 1,901,979,000 | 1,243,336,000 |
| Cost Of Revenue | 25,500,000 | -22,247,000 | — |
| Gross Profit | -29,101,000 | — | — |
| Research And Development Expenses | 1,522,066,000 | 804,522,000 | 877,387,000 |
| General And Administrative Expenses | 491,716,000 | 557,872,000 | 481,871,000 |
| Operating Expenses | 2,898,018,000 | 1,683,898,000 | 1,511,160,000 |
| Operating Income | -699,781,000 | 218,081,000 | -267,824,000 |
| Net Income | -713,410,000 | 235,239,000 | -535,977,000 |
| Earnings Per Share Basic | -7.13 | 2.47 | -5.8 |
| Earnings Per Share Diluted | -7.13 | 2.34 | -5.8 |
| Weighted Average Shares Outstanding Basic | 100,120,000 | 95,075,000 | 92,398,000 |
| Weighted Average Shares Outstanding Diluted | 100,120,000 | 107,875,000 | 92,398,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 940,698,000 | 1,487,955,000 | 1,676,250,000 |
| Marketable Securities Current | 138,368,000 | 251,782,000 | 1,247,820,000 |
| Accounts Receivable | 398,233,000 | 601,988,000 | 400,327,000 |
| Inventories | 914,744,000 | 749,960,000 | 322,859,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 171,856,000 | 90,461,000 | 179,895,000 |
| Total Assets Current | 2,537,938,000 | 3,073,463,000 | 2,579,331,000 |
| Marketable Securities Non Current | 1,048,000 | 133,163,000 | 428,430,000 |
| Property Plant And Equipment | 345,125,000 | 340,336,000 | 227,154,000 |
| Other Assets Non Current | 155,554,000 | 79,915,000 | 136,771,000 |
| Total Assets Non Current | 811,765,000 | 889,710,000 | 685,245,000 |
| Total Assets | 3,349,703,000 | 3,963,173,000 | 3,264,576,000 |
| Accounts Payable | 280,841,000 | 214,442,000 | 164,918,000 |
| Deferred Revenue | 443,397,000 | 130,256,000 | 50,416,000 |
| Short Term Debt | 41,597,000 | 0 | 105,483,000 |
| Other Liabilities Current | 11,393,000 | 13,473,000 | 314,997,000 |
| Total Liabilities Current | 1,095,290,000 | 731,684,000 | 653,659,000 |
| Long Term Debt | 828,974,000 | 1,137,124,000 | 1,237,998,000 |
| Other Liabilities Non Current | 1,529,000 | 1,750,000 | 3,000,000 |
| Total Liabilities Non Current | 1,113,791,000 | 1,703,747,000 | 1,751,580,000 |
| Total Liabilities | 2,209,081,000 | 2,435,431,000 | 2,405,239,000 |
| Common Stock | 11,000 | 10,000 | 9,000 |
| Retained Earnings | -4,876,984,000 | -4,210,974,000 | -4,446,213,000 |
| Accumulated Other Comprehensive Income | 272,000 | -218,000 | 918,000 |
| Total Shareholders Equity | 1,140,622,000 | 1,527,742,000 | 859,337,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 44,521,000 | 37,724,000 | 44,397,000 |
| Share Based Compensation Expense | 123,396,000 | 184,300,000 | 182,514,000 |
| Other Non Cash Income Expense | -7,055,000 | -2,130,000 | -37,000 |
| Change In Accounts Receivable | -203,755,000 | 201,661,000 | 185,699,000 |
| Change In Inventories | 301,093,000 | 395,170,000 | 147,714,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 79,784,000 | 9,676,000 | 10,713,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -205,479,000 | -205,787,000 | -500,993,000 |
| Purchases Of Marketable Securities | 44,658,000 | 1,099,595,000 | 2,044,940,000 |
| Sales Of Marketable Securities | 295,871,000 | 2,002,112,000 | 1,868,482,000 |
| Acquisition Of Property Plant And Equipment | 101,972,000 | 136,956,000 | 76,106,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 69,641,000 | 755,561,000 | -165,803,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 20,000,000 | — | — |
| Repurchase Of Common Stock | 25,013,000 | 0 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | 0 | 0 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -168,344,000 | 124,806,000 | 125,004,000 |
| Change In Cash | -304,182,000 | 674,580,000 | -541,792,000 |
| Cash At End Of Period | 940,698,000 | 1,487,955,000 | 1,676,250,000 |
| Income Taxes Paid | 37,632,000 | 22,587,000 | 15,081,000 |
| Interest Paid | 14,913,000 | 15,856,000 | 15,923,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -7.13 | 2.47 | -5.8 |
| Price To Earnings Ratio | -3.0182 | 49.2267 | -16.6259 |
| Earnings Growth Rate | -388.664 | -142.5862 | -27.7709 |
| Price Earnings To Growth Ratio | 0.0078 | -0.3452 | 0.5987 |
| Book Value Per Share | 11.3925 | 16.0688 | 9.3004 |
| Price To Book Ratio | 1.889 | 7.5668 | 10.3684 |
| Ebitda | -669,397,000 | 277,159,000 | -454,489,000 |
| Enterprise Value | 2,084,455,400 | 11,209,338,250 | 8,577,170,140 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.7632 | 0.7443 | 1.5634 |
| Capital Expenditures | 49,310,000 | 150,906,000 | 91,514,000 |
| Free Cash Flow | -254,789,000 | -356,693,000 | -592,507,000 |
| Return On Equity | -0.6255 | 0.154 | -0.6237 |
| One Year Beta | 1.5019 | 0.35 | 0.9005 |
| Three Year Beta | 1.0955 | 0.8211 | 0.8437 |
| Five Year Beta | 0.9563 | 0.8391 | 0.9308 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Estepan Ian Michael | Chief Operating Officer | 2026-02-26 | 2,069 | A | 195,369 |
| Estepan Ian Michael | Chief Operating Officer | 2026-02-26 | 5,381 | A | 200,750 |
| Estepan Ian Michael | Chief Operating Officer | 2026-02-26 | 2,069 | D | 0 |
| Rodino-Klapac Louise | President, R&D and Tech Ops | 2026-02-25 | 1,875 | A | 8,125 |
| Estepan Ian Michael | Chief Operating Officer | 2026-02-25 | 1,875 | A | 8,125 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2025-05-06 | CA31 | Sale | 2025-04-14 | — | $1,001 - $15,000 |
| Josh Gottheimer | 2023-08-21 | NJ05 | Purchase | 2023-07-14 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2023-07-11 | NJ05 | Sale | 2023-06-13 | Joint | $1,001 - $15,000 |
| Daniel Goldman | 2023-05-19 | NY10 | Sale | 2023-04-10 | — | $15,001 - $50,000 |
| Josh Gottheimer | 2023-04-20 | NJ05 | Purchase | 2023-03-06 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| MV CAPITAL MANAGEMENT, INC. | 2025-12-31 | 2,023 | 94 | 21.5213 |
| Sunbelt Securities, Inc. | 2025-12-31 | 5,358 | 249 | 21.5181 |
| T. Rowe Price Investment Management, Inc. | 2025-12-31 | 19,198,000 | 892,065 | 21.5209 |
| Invesco Ltd. | 2025-12-31 | 8,543,461 | 397,001 | 21.52 |
| Corient Private Wealth LLC | 2025-12-31 | 225,790 | 10,492 | 21.5202 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| LAZARD FUNDS INC | 2025-12-31 | Open Shares | LEOOX | 4 | 40 | 0.0001 |
| LAZARD FUNDS INC | 2025-12-31 | Institutional Shares | LEOIX | 4 | 40 | 0.0001 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCFX | 30,630 | 659,157.6 | 0.6047 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYBOX | 30,630 | 659,157.6 | 0.6047 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYOAX | 30,630 | 659,157.6 | 0.6047 |